SYN - Safety board recommends Synthetic Biologics proceed in cell transplant recipients trial
- Synthetic Biologics ( NYSE: SYN ) on Tuesday said a data safety board had recommended that its phase 1b/2a study of its SYN-004 therapy for the treatment of acute graft-versus-host-disease in stem cell transplant recipients could proceed to enroll patients into the second cohort.
- SYN said the first cohort had enrolled 19 patients who got at least 1 dose of either SYN-004 or a placebo.
- A data safety monitoring committee reviewed the safety and pharmacokinetic data and recommended that the study may proceed to enroll the second cohort in with either SYN-004 or placebo would be administered in combination with antibiotic piperacillin/tazobactam.
- SYN remains on track to initiate the second cohort in Q4, CEO Steven Shallcross said in a statement .
- Synthetic Biologics ( SYN ) stock +4.2% to $1.08 in early trading.
For further details see:
Safety board recommends Synthetic Biologics proceed in cell transplant recipients trial